MYRIAD GENETICS INC
No SEC Form 4 filings for $MYGN in the last 30 days.
See all $MYGN insider activity →Amgen (AMGN) rose 9.5% post-earnings, trading at $225.10. Myriad Genetics (MYGN) reported a 10.5% revenue decline, missing estimates, and fell 25.3% to $4.01. Novavax (NVAX) beat expectations with a 76.3% revenue drop but gained 36.7% to $10.53. Halozyme Therapeutics (HALO) grew revenue 47.7%, beating estimates, and rose 31.5% to $112.81.
AbbVie (NYSE:ABBV) reported Q2 revenue of $16.99B, up 10.2% YoY, beating estimates by 1.2%. Biogen (NASDAQ:BIIB) saw revenue rise 3.4% YoY, exceeding expectations by 12.1%. Myriad Genetics (NASDAQ:MYGN) reported a 10.5% YoY revenue decline, missing estimates by 8.2%. Gilead Sciences (NASDAQ:GILD) reported $7.80B in revenue, up 10.2% YoY, beating estimates by 6.2%. Moderna (NASDAQ:MRNA) reported $145M in revenue, up 2.1% YoY, surpassing expectations by 35.8%.
MYRIAD GENETICS INC (MYGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial SALT LAKE CITY , September 16, 2026 – Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been promo
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning MYGN (MYRIAD GENETICS INC). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent MYGN coverage spans earnings, market movers and corporate actions.
Negative price reaction to earnings miss.
Weak results trigger significant downside pressure.
The executive change is a routine corporate action with limited immediate price impact.
Small upside reflects incremental investor optimism.
Weak earnings and guidance cause steep price decline.
AlphAI scores every news story that mentions MYGN with an AI model for sentiment and relevance, and aggregates insider trades from MYRIAD GENETICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Amgen (AMGN) rose 9.5% post-earnings, trading at $225.10. Myriad Genetics (MYGN) reported a 10.5% revenue decline, missing estimates, and fell 25.3% to $4.01. Novavax (NVAX) beat expectations with a 76.3% revenue drop but gained 36.7% to $10.53. Halozyme Therapeutics (HALO) grew revenue 47.7%, beating estimates, and rose 31.5% to $112.81.
2 min readAbbVie (NYSE:ABBV) reported Q2 revenue of $16.99B, up 10.2% YoY, beating estimates by 1.2%. Biogen (NASDAQ:BIIB) saw revenue rise 3.4% YoY, exceeding expectations by 12.1%. Myriad Genetics (NASDAQ:MYGN) reported a 10.5% YoY revenue decline, missing estimates by 8.2%. Gilead Sciences (NASDAQ:GILD) reported $7.80B in revenue, up 10.2% YoY, beating estimates by 6.2%. Moderna (NASDAQ:MRNA) reported $145M in revenue, up 2.1% YoY, surpassing expectations by 35.8%.
3 min readMYRIAD GENETICS INC (MYGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial SALT LAKE CITY , September 16, 2026 – Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been promo
1 min readRH (NYSE:RH) shares rose 8.2% in pre-market trading after reporting Q2 earnings of $2.70 per share, beating estimates by 51.69%. Revenue was $922.15M, up from last year but below expectations. Other movers included Oracle (NYSE:ORCL), Alliance Entertainment (NASDAQ:AENT), and ACV Auctions (NYSE:ACVA).
3 min readUnited Therapeutics (UTHR) stock rose 4.3% post-earnings, trading at $214.36. Myriad Genetics (MYGN) reported $190.7M revenue, down 10.5% YoY, missing estimates, and guidance fell short, causing a 40.9% stock drop to $3.18. Gilead Sciences (GILD) reported $7.8B revenue, up 10.2% YoY, beating estimates, with stock up 8.1% to $146.16. Novavax (NVAX) reported $56.7M revenue, down 76.3% YoY, but beat estimates, with stock up 32.2% to $10.18.
3 min readBlackRock Portfolio Management LLC now owns 10.4% of Myriad Genetics' (MYGN) common stock, with sole voting power over 8,751,792 shares and sole dispositive power over 9,900,937 shares. No single client holds more than 5% of MYGN's outstanding shares.
2 min readMyriad Genetics (MYGN) shares fell 7.1% premarket after Piper Sandler downgraded the stock to Underweight, cutting its price target to $2.00 from $5.45. The firm cited concerns over the company's profitability and weak Q2 2026 results, including a 10.5% year-over-year revenue decline. The broader market also declined, with the NASDAQ down 0.9%.
2 min readBioMarin Pharmaceutical (BMRN) rose 6.9% after Q2 results. Myriad Genetics (MYGN) fell 41.8% with revenue down 10.5% YoY, missing estimates. Halozyme Therapeutics (HALO) gained 25% with revenue up 47.7% YoY, beating expectations. Vertex Pharmaceuticals (VRTX) increased 16.3% with revenue up 12.5% YoY, topping forecasts.
3 min readRoblox (RBLX), Hertz (HTZ) and Myriad Genetics (MYGN) fell to 52-week lows as investors cited weaker outlooks and operational issues. RBLX dropped after Q2 revenue of $1.47B missed expectations and it withdrew its 2026 outlook. HTZ slid on margin pressure and $11.6B debt. MYGN sank after Q2 revenue of $190.7M missed and it cut its full-year forecast.
4 min readSimply Wall St reports Myriad Genetics (MYGN) shares are down 49% after the company cut its 2026 revenue outlook, citing weakness in prenatal testing. The piece references analyst fair value estimates and highlights potential positive and negative factors for investors, but provides no specific new financial figures beyond the outlook cut.
2 min read
